Development of a predictive model for FIC index of meropenem-colistin combination against carbapenem-resistant Acinetobacter baumannii
Các tác giả
DOI: https://doi.org/10.59294/HIUJS2025024Từ khóa:
Acinetobacter baumannii, meropenem-colistin, FIC index, predictive modelTóm tắt
Background: Acinetobacter baumannii represents a critical antimicrobial resistance challenge in Vietnamese healthcare settings, with carbapenem resistance rates reaching 55-90%. Traditional checkerboard methodology for evaluating antibiotic combinations requires substantial time and resources, limiting routine application in research settings. Objective: To develop a predictive model for the FIC index of meropenem-colistin combination based on MIC values. Methods: A cross-sectional analytical study on 61 carbapenem-resistant A. baumannii strains (6/2022 - 12/2022). MICs were determined by broth microdilution, and synergy was evaluated through FIC index. Eight regression models were compared using 80/20 train-test split with 5-fold cross-validation for stability assessment. Results: All strains were resistant to meropenem but intermediate to colistin. The combination showed synergy in 77% and additivity in 23%. A logarithmic model FIC = 0.649 - 0.155 × ln(Mero) - 0.227 × ln(Col) achieved high accuracy (R² = 0.554). The model demonstrated 95% sensitivity and 75% specificity for synergy prediction with an overall classification accuracy of 88.5%. Conclusion: This is the first study applying machine learning for quantitative FIC prediction. While offering potential research applications, clinical implementation requires extensive validation, given recent evidence against therapeutic efficacy of this combination.
Abstract
Background: Acinetobacter baumannii represents a critical antimicrobial resistance challenge in Vietnamese healthcare settings, with carbapenem resistance rates reaching 55-90%. Traditional checkerboard methodology for evaluating antibiotic combinations requires substantial time and resources, limiting routine application in research settings. Objective: To develop a predictive model for the FIC index of meropenem-colistin combination based on MIC values. Methods: A cross-sectional analytical study on 61 carbapenem-resistant A. baumannii strains (6/2022 - 12/2022). MICs were determined by broth microdilution, and synergy was evaluated through FIC index. Eight regression models were compared using 80/20 train-test split with 5-fold cross-validation for stability assessment. Results: All strains were resistant to meropenem but intermediate to colistin. The combination showed synergy in 77% and additivity in 23%. A logarithmic model FIC = 0.649 - 0.155 × ln(Mero) - 0.227 × ln(Col) achieved high accuracy (R² = 0.554). The model demonstrated 95% sensitivity and 75% specificity for synergy prediction with an overall classification accuracy of 88.5%. Conclusion: This is the first study applying machine learning for quantitative FIC prediction. While offering potential research applications, clinical implementation requires extensive validation, given recent evidence against therapeutic efficacy of this combination.
Tài liệu tham khảo
[1] N. Teerawattanapong, P. Panich, D. Kulpokin…and N. Chaiyakunapruk, "A systematic review of the burden of multidrug-resistant healthcare-associated infections among intensive care unit patients in Southeast Asia: the rise of multidrug-resistant Acinetobacter baumannii," Infection Control & Hospital Epidemiology, vol. 39, no. 5, pp. 525-533, 2018. DOI: 10.1017/ice.2018.58.
DOI: https://doi.org/10.1017/ice.2018.58[2] N. T. K. Nhu, N. P. H. Lan, J. I. Campbell…and S. Baker, "Emergence of carbapenem-resistant Acinetobacter baumannii as the major cause of ventilator-associated pneumonia in intensive care unit patients at an infectious disease hospital in southern Vietnam," Journal of Medical Microbiology, vol. 63, no. 10, pp. 1386-1394, 2014. DOI: 10.1099/jmm.0.076646-0.
DOI: https://doi.org/10.1099/jmm.0.076646-0[3] P. J. Bergen, B. T. Tsuji, J. B. Bulitta…and J. Li, "Synergistic killing of multidrug-resistant Pseudomonas aeruginosa at multiple inocula by colistin combined with doripenem in an in vitro pharmacokinetic/pharmacodynamic model," Antimicrobial Agents and Chemotherapy, vol. 55, no. 12, pp. 5685-5695, 2011. DOI: 10.1128/AAC.05298-11.
DOI: https://doi.org/10.1128/AAC.05298-11[4] M. Paul, G. L. Daikos, E. Durante-Mangoni…and L. Leibovici, "Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial," The Lancet Infectious Diseases, vol. 18, no. 4, pp. 391-400, 2018. DOI: 10.1016/S1473-3099(18)30099-9.
DOI: https://doi.org/10.1016/S1473-3099(18)30099-9[5] K. S. Kaye, D. Marchaim, V. Thamlikitkul…and J. M. Pogue, "Colistin monotherapy versus combination therapy for carbapenem-resistant organisms," NEJM Evidence, vol. 2, no. 1, p. EVIDoa2200131, 2023. DOI: 10.1056/EVIDoa2200131.
DOI: https://doi.org/10.1056/EVIDoa2200131[6] A. E. Maraolo and D. S. Ong, "Colistin plus meropenem versus colistin alone for invasive infections caused by carbapenem-resistant Acinetobacter baumannii: a rapid systematic review of randomized controlled trials using Bayesian meta-analysis," Clinical Microbiology and Infection, vol. 29, no. 9, pp. 1208-1210, 2023. DOI: 10.1016/j.cmi.2023.05.036.
DOI: https://doi.org/10.1016/j.cmi.2023.05.036[7] J. C. Abdul-Mutakabbir, J. Yim, L. Nguyen…and M. J. Rybak, "In vitro synergy of colistin in combination with meropenem or tigecycline against carbapenem-resistant Acinetobacter baumannii," Antibiotics, vol. 10, no. 7, p. 880, 2021. DOI: 10.3390/antibiotics10070880.
DOI: https://doi.org/10.3390/antibiotics10070880[8] C. Huang, I. Chen, and T. Tang, "Colistin monotherapy versus colistin plus meropenem combination therapy for the treatment of multidrug-resistant Acinetobacter baumannii infection: a meta-analysis," Journal of Clinical Medicine, vol. 11, no. 11, p. 3239, 2022. DOI: 10.3390/jcm11113239.
DOI: https://doi.org/10.3390/jcm11113239[9] T. A. Hafiz, S. S. Alghamdi, M. A. Mubaraki…and F. Alotaibi, "A two-year retrospective study of multidrug-resistant Acinetobacter baumannii respiratory infections in critically Ill patients: Clinical and microbiological findings," Journal of Infection and Public Health, vol. 16, no. 3, pp. 313-319, 2023. DOI: 10.1016/j.jiph.2023.01.004.
DOI: https://doi.org/10.1016/j.jiph.2023.01.004[10] A. M. Aboshakwa, U. Lalla, E. M. Irusen and C. F. N. Koegelenberg, "Acinetobacter baumannii infection in a medical intensive care unit: The impact of strict infection control," African Journal of Thoracic and Critical Care Medicine, vol. 25, no. 1, pp. 10-13, 2019. DOI: 10.7196/AJTCCM.2019.v25i1.239.
DOI: https://doi.org/10.7196/SARJ.2019.v25i1.239[11] Z. Jiang, X. He, and J. Li, "Synergy effect of meropenem-based combinations against Acinetobacter baumannii: a systematic review and meta-analysis," Infection and Drug Resistance, pp. 1083-1095, 2018. DOI: 10.2147/IDR.S172137.
DOI: https://doi.org/10.2147/IDR.S172137[12] M. Nguyen, T. Brettin, S. W. Long...and J. J. Davis, "Developing an in silico minimum inhibitory concentration panel test for Klebsiella pneumoniae," Sci Rep, vol. 8, no. 1, p. 421, 2018, DOI: 10.1038/s41598-017-18972-w.
DOI: https://doi.org/10.1038/s41598-017-18972-w[13] M. Nguyen, S. W. Long, P. F. McDermott...and J. J. Davis, "Using Machine Learning To Predict Antimicrobial MICs and Associated Genomic Features for Nontyphoidal Salmonella," J Clin Microbiol, vol. 57, no. 2, 2019, DOI: 10.1128/JCM.01260-18.
DOI: https://doi.org/10.1128/JCM.01260-18[14] A. Rajput, K. T. Bhamare, A. Thakur, and M. Kumar, "Anti-Biofilm: Machine Learning Assisted Prediction of IC(50) Activity of Chemicals Against Biofilms of Microbes Causing Antimicrobial Resistance and Implications in Drug Repurposing," J Mol Biol, vol. 435, no. 14, p. 168115, 2023, DOI: 10.1016/j.jmb.2023.168115.
DOI: https://doi.org/10.1016/j.jmb.2023.168115[15] E. C. f. A. S. T. o. t. E. S. o. C. Microbiology and I. Diseases, "Determination of minimum inhibitory concentrations (MICs) of antibacterial agents by broth dilution," Clinical Microbiology and Infection, vol. 9, no. 8, pp. ix-xv, 2003, DOI: https://doi.org/10.1046/j.1469-0691.2003.00790.x.
DOI: https://doi.org/10.1046/j.1469-0691.2003.00790.x
Tải xuống
Tải xuống: 30
Đã xuất bản
Cách trích dẫn
Số
Chuyên mục
